Skip to main content

Advertisement

Table 2 Clinician-reported Patient Clinical Characteristics

From: The content validity of the ANMS GCSI-DD in patients with idiopathic or diabetic gastroparesis

Characteristic Total (N = 25) IG (N = 15) DG (N = 10)
Time in clinician’s practice (years)
 Mean (SD) 2.7 (3.7) 0.9 (1.2) 5.3 (4.5)
 Range (Min, Max) (0.1, 13.6) (0.1, 4.2) (0.5, 13.6)
Duration of diagnosis (years)
 Mean (SD) 1.7 (1.8) 1.7 (2.0) 1.8 (1.6)
 Range (Min, Max) (0.2, 7.0) (0.2, 7.0) (0.4, 4.8)
Current medications for gastroparesis, n (%)a
 Gastric antisecretory agent 11 (44.0%) 7 (46.7%) 4 (40.0%)
 Prokinetic agent 9 (36.0%) 6 (40.0%) 3 (30.0%)
 Antiemetic agent 9 (36.0%) 7 (46.7%) 2 (20.0%)
 Diabetes medical treatment 7 (28.0%) 0 (0.0%) 7 (70.0%)
 Pain medications 5 (20.0%) 5 (33.3%) 0 (0.0%)
 Psychotropic agent 4 (16.0%) 3 (20.0%) 1 (10.0%)
 Gastric electric stimulation (pacemaker) 1 (4.0%) 0 (0.0%) 1 (10.0%)
 Otherb 4 (16.0%) 4 (26.7%) 0 (0.0%)
Prior GI specific surgeries, n (%)
 Gastric electric stimulation (GES) 1 (4.0%) 0 (0.0%) 1 (10.0%)
 Otherc 3 (12.0%) 2 (13.3%) 1 (10.0%)
 None 21 (84.0%) 13 (86.7%) 8 (80.0%)
Time since most recent upper endoscopy (years)
 Mean (SD) 1.2 (1.5) 1.2 (1.6) 1.2 (1.2)
 Range (Min, Max) (0.0, 5.9) (0.1, 5.9) (0.0, 3.3)
Physician rating of gastroparesis severity, n (%)
 None 0 (0.0%) 0 (0.0%) 0 (0.0%)
 Very mild 3 (12.0%) 1 (6.7%) 2 (20.0%)
 Mild 10 (40.0%) 4 (26.7%) 6 (60.0%)
 Moderate 9 (36.0%) 7 (46.7%) 2 (20.0%)
 Severe 3 (12.0%) 3 (20.0%) 0 (0.0%)
 Very severe 0 (0.0%) 0 (0.0%) 0 (0.0%)
Comorbid conditions, n (%)a
 Obesity 8 (32.0%) 4 (26.7%) 4 (40.0%)
 Other gastrointestinal disorder (other than gastroparesis)d 7 (28.0%) 4 (26.7%) 3 (30.0%)
 Mood disorder or mental health condition 4 (16.0%) 3 (20.0%) 1 (10.0%)
 Insomnia/sleep problems 4 (16.0%) 4 (26.7%) 0 (0.0%)
 Respiratory condition 4 (16.0%) 3 (20.0%) 1 (10.0%)
 Cardiovascular condition 3 (12.0%) 1 (6.7%) 2 (20.0%)
 Dyslipedemia/hyperlipidemia 3 (12.0%) 0 (0.0%) 3 (30.0%)
 Neurological condition 1 (4.0%) 0 (0.0%) 1 (10.0%)
 Otherd 4 (16.0%) 3 (20.0%) 1 (10.0%)
 None 3 (12.0%) 2 (13.3%) 1 (10.0%)
  1. aNot mutually exclusive
  2. bOther treatment: Azithromycin, Metoclopramide, Lansoprazole; Botox injection of pyloris; Linaclotide; nasojejunal (NJ) tube, Pantoprazole
  3. cOther GI surgery: Cholecystectomy
  4. dOther co-morbidity: Fibromyalgia, Iron Deficiency Anemia, Iron Deficiency Anemia, Lyme Disease; Fibromyalgia, Chronic fatigue syndrome, Postural orthostatic tachycardia syndrome (POTS)